The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
The MM Hub were delighted to attend the 59th American Society of Hematology (ASH) Annual Meeting held in Atlanta, Georgia, from 9-12 December 2017. On Sunday 10 December, an oral session was held and entitled: Session: 653. Myeloma: Therapy, excluding Transplantation: Upfront Therapy for Multiple Myeloma: Induction and Maintenance. During this session, an oral abstract was presented by Sonja Zweegman from the Department of Hematology, VUMC, Amsterdam, Netherlands. The title of the talk was: Abstract 433: Ixazomib-Thalidomide-Low Dose Dexamethasone (ITd) Induction Followed by Maintenance Therapy with Ixazomib or Placebo in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Autologous Stem Cell Transplantation; Initial Results from the Randomized Phase II HOVON-126/Nmsg 21.13 Trial.
Professor Zweegman began her talk by outlining the rationale for the ongoing Phase II HOVON study. With the combination of a proteasome inhibitor (PI) and an IMiD having shown significant efficacy in Newly Diagnosed Multiple Myeloma (NDMM) patients, such a combo is an obvious option for elderly patients who are not eligible for transplant. However, keeping adverse effects to a minimum is critical in this patient subset and so the use of ixazomib as the relevant PI provides the added benefit of an all-oral combination. Therefore, elderly non-transplant eligible (nte) NDMM were given ixazomib induction therapy in combination with thalidomide, followed by maintenance therapy with either ixazomib or placebo.
The primary endpoints of the study were progression free survival (PFS) for maintenance therapy with ixazomib or placebo, and the overall response rate (ORR) of induction therapy. The preliminary results of the study after an early interim analysis were outlined.
The talk was concluded by Professor Zweegman summarizing the overall finding that induction treatment with ITd in NDMM led to a high ORR of 81%, with 44% ≥ VGPR. It was emphasized that this was equally effective in subgroup analyses via frailty and high-risk cytogenetics. This regimen, therefore, offers a valid and manageable frontline therapy for MM patients who are ineligible for transplant.
To listen to Professor Zweegman discussing this study click here.
References